Shares of Zai Lab Ltd (ZLAB) surged 5.5% in Thursday's extended trading session, outperforming the broader market despite missing earnings expectations for the fourth quarter of 2024. The rally was fueled by the biopharmaceutical company's robust revenue growth and a positive outlook from Wall Street analysts.
In its latest quarterly report, Zai Lab posted an adjusted loss of $0.80 per share, wider than the consensus estimate of a $0.65 loss. However, the company's top line grew an impressive 64.8% year-over-year to $108.51 million, driven by strong demand for its innovative cancer treatments and other therapies.
While the earnings miss was a slight disappointment, analysts remained overwhelmingly bullish on Zai Lab's prospects. The average analyst rating on the stock is a "Buy," with a median 12-month price target of $50, representing significant upside potential from current levels. Analysts cited the company's promising pipeline, expanding geographic footprint, and solid execution as key growth drivers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.